Press archive
The 20 recent news
07/01/09, Levitra Bayer files patent infringement lawsuit against Teva Leverkusen, July 1, 2009 – Bayer Schering Pharma AG, Germany and Bayer HealthCare Pharmaceuticals Inc. together with Schering Corporation have filed a patent infringement lawsuit in the U.S. Fe... External Link: more
06/29/09, Oncology Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets License Agreement with Celera Corporation on five cancer target molecules External Link: more
06/12/09, Diagnostic Imaging Bayer completes Phase II Study on BAY 94-9172 in Alzheimer’s Disease Imaging Diagnostic Imaging Using Positron Emission Tomography (PET) External Link: more
06/10/09, Breeze Discovering Europe on two wheels Diabetic Paul Farelly finished his European Cycle Challenge from Portsmouth to Istanbul External Link: more
06/02/09, Oncology Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreement Berlin, Germany and Tarrytown, NY, USA, June 2, 2009 – Bayer HealthCare and Genzyme Corporation said today that they have received regulatory approvals for the strategic alliance announced on M... External Link: more
06/01/09, Oncology Bayer and Onyx Initiate Phase III Trial of Nexavar® in Non-small Cell Lung Cancer Berlin, June 1, 2009 – Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexava... External Link: more
05/30/09, Research & Development Bayer Schering Pharma Announces New Data on Novel Anti-cancer Compound BAY 73-4506 Abstracts #: 5033 and 3560 Orlando, Florida, USA and Berlin, Germany, May 30, 2009 – Bayer Schering Pharma AG today announced results from Phase I and II trials of BAY 73-4506, a potent oral mu... External Link: more
05/28/09, Bayer HealthCare European Journalists’ Prize goes to Volker Stollorz Award sponsored by the Association of German Medical Journalists (VDMJ) and Bayer HealthCare AG External Link: more
05/28/09, Xarelto U.S. FDA Issues Complete Response Letter for Rivaroxaban No new clinical or non-clinical studies to be conducted as a pre-requisite for approval External Link: more
05/28/09, Oncology Phase III Trial Started to Evaluate Combination Therapy of Nexavar® and Tarceva® in Patients with Liver Cancer Berlin, May 28, 2009 – Bayer HealthCare AG, Onyx Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. and Roche today announced the initiation of a Phase III trial examining Nexavar® (sorafenib) t... External Link: more
05/22/09, Oncology Bayer Schering Pharma To Present Data on Oncology Development Compound BAY 73-4506 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) External Link: more
05/20/09, Oncology Nexavar® Approved in Japan for the Treatment of Advanced Liver Cancer Berlin, May 20, 2009 – Bayer received approval in Japan for Nexavar® (sorafenib) tablets for the treatment of unresectable hepatocellular carcinoma (HCC) from the Ministry of Health, Labour an... External Link: more
05/19/09, Research & Development Bayer Schering Pharma presents positive results of phase II study with Riociguat San Diego, USA / Berlin, Germany, May 19, 2009 – Positive data from a phase II trial with Bayer Schering Pharma’s oral agent riociguat (BAY 63-2521) in chronic thromboembolic pulmonary hy... External Link: more
05/15/09, Oncology Bayer and Onyx Announce Nexavar® Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting Berlin, May 15, 2009 – Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that more than 65 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the ... External Link: more
05/14/09, Research & Development Qlaira® – innovative estradiol-based oral contraceptive available in Europe from May onwards A new oral contraceptive delivering the same estrogen as produced by the female body External Link: more
05/05/09, Research & Development Bayer Schering Pharma is starting Phase III studies with an innovative low-dose contraceptive patch Berlin, May 5, 2009 – Bayer Schering Pharma AG, Germany is starting Phase III with an innovative patch for female contraception that combines low dosed ethinylestradiol and gestodene. Approxima... External Link: more
04/30/09, Diabetes “With the right motivation, you can reach your goal” Bayer Diabetes Care DreamFund™ winner cycles 2,000 miles across Europe External Link: more
04/30/09, Research & Development Bayer and Regeneron extend development program for VEGF Trap-Eye Two phase III studies in Central Retinal Vein Occlusion (CRVO) to begin in the second half of this year External Link: more
04/29/09, Bayer HealthCare CropScience and Pharmaceuticals continue on a path of growth – Slump in business at MaterialScience leaves a distinct mark Group sales: EUR 7,895 million (minus 7.5 percent) / EBITDA before special items: EUR 1,695 million (minus 22.4 percent) / EBIT before special items: EUR 1,017 million (minus 32.1 percent) / Net cash... External Link: more
04/28/09, Research & Development Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer Berlin, April 28, 2009 – Bayer HealthCare AG, Germany has entered into a global agreement with Ardea Biosciences, Inc., San Diego California, USA (Nasdaq: RDEA) focused on the development of sm... External Link: more
top of page